Sign up Australia
Proactive Investors - Run By Investors For Investors

Immunovaccine breaking ground, says Mackie, as it rates stock 'speculative buy'

Mackie reckons the firm is 'breaking ground' and targets C$2.80 for the shares..
Immunovaccine breaking ground, says Mackie, as it rates stock 'speculative buy'
The firm is operating in the field of immunology..

Broker Mackie repeated a 'speculative buy' stance on Immunovaccine Inc (TSE:IMV) following news that it was advancing its cancer vaccine into a Phase I trial.

The biotech announced an expansion of its ongoing collaboration with UConn Health  - part of Immunovaccine’s DPX-NEO program.

This is assessing the anti-cancer activity of patient specific epitopes (the part of molecule which is the target of an immune response) developed at UConn Health and formulated in Immunovaccine's proprietary delivery system.

“The potential of neoepitope-based therapies to trigger anti-cancer immune responses tailored to the unique biology of each patient’s disease could be an oncology treatment game-changer,” said Frederic Ors, Immunovaccine’s chief executive today.

Mackie agrees the firm is 'breaking ground'  and targets C$2.80 for the shares, against a current price of C$2.13 - up over 11% on the day.

DPX-NEO should diversify the group's pipeline once it enters a Phase I study, says analyst Andre Uddin, who adds there are multiple catalysts ahead for the group.

"IMV has been up 181% YTD and our call has generated a 208% return since we launched coverage," he notes.

View full IMV profile View Profile

ImmunoVaccine Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use